Haloperidol decanoate
As of the edition of 20 October 2026, Haloperidol decanoate is a small molecule: marketed, first approved in 1986 (US); acts on DRD2, DRD3 and DRD4 and 1 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1986
- Kind
- Small molecule
- Brand name
- Haldol
- First approved
- 14 January 1986 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Johnson & Johnson
- Registered trials
- 6, 1 stopped early
- Disease areas
- Mental health; Nervous system; Blood and lymph; Cancer; Chemically induced
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Haloperidol decanoate.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 2 | 0 | 0 |
| Phase 2 | 1 | 0 | 1 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 2 | 1 | 0 | 1 |
| All trials | 6 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Johnson & Johnson | Acquired holder | 2011 to now |